基于B7-H3靶点的分子影像技术在肿瘤诊断方面的研究进展  

Advances in molecular imaging of B7-H3-targeted in context of tumor diagnostic

作　　者：郑梦 王燕[1,2] 傅丰庆[1,3] 缪丽燕(指导)[1,2] ZHENG Meng;WANG Yan;FU Fengqing;MIAO Liyan(The First Affiliated Hospital of Soochow University,Suzhou 215006,China)

机构地区：[1]苏州大学附属第一医院,苏州215006 [2]苏州大学药物研究与转化交叉研究所,苏州215123 [3]苏州大学放射医学与辐射防护国家重点实验室,苏州215123

出　　处：《中国免疫学杂志》2023年第11期2439-2445,共7页Chinese Journal of Immunology

基　　金：国家自然科学基金项目(82104318);江苏省重点研发计划(社会发展)专项(BE2021644)。

摘　　要：寻找新的治疗靶点用于准确的癌症早期诊断是目前肿瘤精准治疗亟待解决的问题之一。B7-H3(CD276)曾被称为“肿瘤相关抗原”,在肿瘤组织中广泛异常高表达,在正常组织上表达受限,使其成为各种靶向肿瘤的造影剂及肿瘤治疗的理想分子。分子影像通过分子影像探针以非侵入性形式显示肿瘤病理生理特征,可用于诊断、治疗及各种靶向治疗(包括免疫治疗)的效果评估。因此,本文主要综述以B7-H3为靶点的分子影像在肿瘤诊断中的最新研究进展。Looking for a cancer therapeutic targeted used in diagnosis is in the spotlight as one solution in the precise fight against cancer.B7-H3(CD276)was once known as a"tumor-associated antigen",which is aberrantly expressed in a high proportion of human malignancies but limited expression in normal human tissues,making it an ideal target for various contrast agents and cancer treatment.Molecular imaging with molecular imaging probes,noninvasively,demonstrate pathophysiologic features of cancer for diagnostic,treatment,and response assessment considerations for various targeted therapies,including immunotherapy.Herein,we review the latest developments in molecular imaging of B7-H3 targeted in the context of cancer diagnostic.

关 键 词：B7-H3(CD276) 分子影像 肿瘤 探针 靶向治疗 早期诊断 

分 类 号：R392-33[医药卫生—免疫学]